Duvelisib + Nivolumab for Skin Cancer
Trial Summary
What is the purpose of this trial?
This trial tests duvelisib and nivolumab in patients with advanced mycosis fungoides and Sezary syndrome. Duvelisib blocks cancer cell growth, and nivolumab boosts the immune system to fight cancer. The goal is to find the best dose and see if this combination works better than current treatments.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you must stop all current medications, but there are some restrictions. You cannot be on strong inhibitors or inducers of CYP3A4, and you must stop any systemic therapy for MF/SS with specific washout periods: 8 weeks for low-dose total skin electron beam therapy, 4 weeks for systemic cytotoxic agents or tumor-targeting monoclonal antibodies (except alemtuzumab, which is 16 weeks), 2 weeks or 5 half-lives for systemic retinoids and other specified agents, 2 weeks for local radiation, and 1 week for topical retinoids and other specified topical treatments. You can continue using inhaled steroids and certain topical steroids if stable for at least 4 weeks. Please consult with the trial team for guidance on your specific medications.
Will I have to stop taking my current medications?
The trial does not specify if you must stop all current medications, but you cannot take certain medications like strong inhibitors or inducers of CYP3A4, and some immunosuppressive drugs. There are specific 'washout' periods for certain treatments, such as 4 weeks for some anticancer agents and 1 week for topical treatments.
What data supports the idea that Duvelisib + Nivolumab for Skin Cancer is an effective treatment?
The available research shows that Nivolumab, one of the drugs in the Duvelisib + Nivolumab combination, has been effective in treating advanced melanoma, a type of skin cancer. It was the first drug of its kind to show long-term survival benefits in clinical trials for advanced melanoma patients. However, there is no specific data provided on the combination of Duvelisib and Nivolumab for skin cancer in the information available.12345
What data supports the effectiveness of the drug combination Duvelisib and Nivolumab for skin cancer?
Nivolumab (Opdivo) has shown long-term survival benefits in patients with advanced melanoma, a type of skin cancer, as it was the first drug to demonstrate this in clinical trials. Additionally, Nivolumab has been effective in improving survival when used in combination with other drugs for different types of cancer, suggesting potential benefits when combined with Duvelisib for skin cancer.12345
What safety data is available for the combination of Duvelisib and Nivolumab in treating skin cancer?
The provided research does not directly address the safety data for the combination of Duvelisib and Nivolumab specifically for skin cancer. However, it includes information on the safety profile of Nivolumab, which is used in combination therapies. Nivolumab has been associated with adverse reactions such as fatigue, diarrhea, constipation, nausea, musculoskeletal pain, rash, and pruritus. Additionally, dermatological adverse events have been reported with Nivolumab in combination with other drugs, such as rash and pruritus. No specific safety data for Duvelisib or its combination with Nivolumab is mentioned in the provided research.678910
What safety information is available for the combination of Duvelisib and Nivolumab in humans?
Is the drug Duvelisib, Nivolumab a promising treatment for skin cancer?
How is the drug combination of Duvelisib and Nivolumab unique for treating skin cancer?
The combination of Duvelisib and Nivolumab for skin cancer is unique because it combines a PI3K inhibitor (Duvelisib) with a PD-1 immune checkpoint inhibitor (Nivolumab), potentially enhancing the immune system's ability to fight cancer cells. This approach is different from traditional chemotherapy and surgery, offering a novel mechanism by targeting specific pathways involved in cancer growth and immune evasion.18111213
Research Team
Neha Mehta-Shah
Principal Investigator
Yale University Cancer Center LAO
Eligibility Criteria
Adults over 18 with stage IIB-IVB mycosis fungoides or Sezary syndrome who've had prior systemic therapy can join this trial. They must have certain levels of blood cells, kidney and liver function, and controlled brain metastases if present. Heart disease patients need a specific risk assessment. Participants must use effective contraception and not be pregnant or breastfeeding.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive duvelisib orally and nivolumab intravenously in 28-day cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Duvelisib
- Nivolumab
Duvelisib is already approved in United States for the following indications:
- Relapsed or refractory chronic lymphocytic leukemia (CLL)
- Relapsed or refractory small lymphocytic lymphoma (SLL)
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor